Semin Liver Dis 2005; 25(2): 181-200
DOI: 10.1055/s-2005-871198
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Resection and Liver Transplantation for Hepatocellular Carcinoma

Josep M. Llovet1 , 2 , Myron Schwartz2 , Vincenzo Mazzaferro3
  • 1Senior Researcher, BCLC Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Clínic, University of Barcelona, Catalonia, Spain
  • 2Division of Liver Diseases and Recanati Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York
  • 3G.I. Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy
Further Information

Publication History

Publication Date:
25 May 2005 (online)

ABSTRACT

Surveillance programs in cirrhotic patients enable the detection of hepatocellular carcinoma (HCC) at early stages, when the tumor is amenable to curative treatments (60% of cases in Japan; 25 to 40% in Europe and the United States). Resection is the mainstay of treatment in noncirrhotic patients and in cirrhotics with well-preserved liver function. In modern series, a perioperative mortality ≤ 3% and 5-year survival rates above 50% are expected. Tumor recurrence complicates half of the cases at 3 years, but there is no unquestionable preventive treatment. Liver transplantation provides excellent outcomes applying the Milan criteria (single nodule ≤ 5 cm or two or three nodules ≤ 3 cm), with 5-year survival rates of 70% and low recurrence rates. Although expansion of selection criteria is appealing, it should be assessed in the setting of prospective well-designed studies. Intention-to-treat analysis has shown that wide extended indications lead to 25% 5-year survival rates. Living donor liver transplantation is having a minor impact in HCC management. Molecular markers are needed to better select the candidates for surgery.

REFERENCES

  • 1 Parkin D M, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000.  Int J Cancer. 2001;  94 153-156
  • 2 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med. 1999;  340 745-750
  • 3 Bosch F X, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 S5-S16
  • 4 Sangiovanni A, Del Ninno E, Fasani P et al.. Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance.  Gastroenterology. 2004;  126 1005-1014
  • 5 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma.  Lancet. 2003;  362 1907-1917
  • 6 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference.  J Hepatol. 2001;  35 421-430
  • 7 Llovet J M, Bustamante J, Castells A et al.. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.  Hepatology. 1999;  29 62-67
  • 8 Villa E, Moles A, Ferretti I et al.. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival.  Hepatology. 2000;  32 233-238
  • 9 Takayama T, Makuuchi S, Hirohashi S et al.. Early hepatocellular carcinoma as an entity with high rate of surgical cure.  Hepatology. 1998;  28 1241-1246
  • 10 Fong Y, Sun R L, Jarnagin W, Blumgart L H. An analysis of 412 cases of hepatocellular carcinoma at a Western center.  Ann Surg. 1999;  229 790-799
  • 11 Llovet J M, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.  Hepatology. 1999;  30 1434-1440
  • 12 Arii S, Yamaoka Y, Futagawa S et al.. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan.  Hepatology. 2000;  32 1224-1229
  • 13 Zhou X D, Tang Z Y, Yang B H et al.. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma.  Cancer. 2001;  91 1479-1486
  • 14 Poon R T, Fan S T, Lo C M et al.. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.  Ann Surg. 2002;  235 373-382
  • 15 Wayne J D, Lauwers G Y, Ikai I et al.. Preoperative predictors of survival after resection of small hepatocellular carcinomas.  Ann Surg. 2002;  235 722-731
  • 16 Kianmanesh R, Regimbeau J M, Bekghiti J. Selective approach to major hepatic resection for hepatocellular carcinoma on chronic liver disease.  Surg Oncol Clin N Am. 2003;  12 51-63
  • 17 Ercolani G, Grazi G L, Ravaioli M et al.. Liver resection for hepatocellular carcinoma on cirrhosis.  Ann Surg. 2003;  237 536-543
  • 18 Ikai I, Arii S, Kojiro M et al.. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.  Cancer. 2004;  101 796-802
  • 19 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334 693-699
  • 20 Bismuth H, Majno P E, Adam R. Liver transplantation for hepatocellular carcinoma.  Semin Liver Dis. 1999;  19 311-322
  • 21 Jonas S, Bechstein W O, Steinmuller T et al.. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.  Hepatology. 2001;  33 1080-1086
  • 22 Yao F Y, Ferrell L, Bass N M et al.. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival.  Hepatology. 2001;  33 1394-1403
  • 23 Adam R, Azoulay D, Castaing D et al.. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?.  Ann Surg. 2003;  238 508-519
  • 24 Hemming A W, Nelson D R, Reed A I. Liver transplantation for hepatocellular carcinoma.  Minerva Chir. 2002;  57 575-585
  • 25 Shetty K, Timmins K, Brensinger C et al.. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome.  Liver Transpl. 2004;  10 911-918
  • 26 Herrero J I, Sangro B, Quiroga J et al.. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.  Liver Transpl. 2001;  7 631-636
  • 27 Roayaie S, Frischer J, Emre S H et al.. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 cm.  Ann Surg. 2002;  235 533-539
  • 28 Marsh J W, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?.  Liver Transpl. 2003;  9 693-696
  • 29 Molmenti E, Klintmalm G. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry.  Liver Transpl. 2002;  8 736-748
  • 30 Cillo U, Vitale A, Bassanello M et al.. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.  Ann Surg. 2004;  239 150-159
  • 31 National Cancer Institute website, U.S. National Institutes of Health . http://www.cancer.gov
  • 32 Kaihara S, Kiuchi T, Ueda M et al.. Living donor liver transplantation for hepatocellular carcinoma.  Transplantation. 2003;  75 S37-S40
  • 33 Gondolesi G, Roayaie S, Muñoz L et al.. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria.  Ann Surg. 2004;  239 142-149
  • 34 Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan.  Ann Surg. 2004;  240 451-461
  • 35 Llovet J M, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival.  Hepatology. 2003;  37 429-442
  • 36 Llovet J M, Real M I, Montaña X et al.. Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial.  Lancet. 2002;  359 1734-1739
  • 37 Belghiti J, Hiramatsu K, Benoist S. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.  J Am Coll Surg. 2000;  191 38-46
  • 38 Bralet M P, Regimbeau J M, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.  Hepatology. 2000;  32 200-204
  • 39 Bismuth H, Majno P E. Hepatobiliary surgery.  J Hepatol. 2000;  32(1 suppl) 208-224
  • 40 Song T, Ip E, Fong Y. Hepatocellular carcinoma: current surgical management.  Gastroenterology. 2004;  127 S248-S260
  • 41 Marin-Hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results.  Crit Rev Oncol Hematol. 2003;  47 13-27
  • 42 Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan.  Liver Transpl. 2004;  10 S46-S52
  • 43 Torzilli G, Makuuchi M, Inoue K et al.. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.  Arch Surg. 1999;  134 984-992
  • 44 Fan S T, Lo C M, Liu C L et al.. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.  Ann Surg. 1999;  229 322-330
  • 45 Sobin LH, Wittekind C TNM Classification of Malignant Tumors. 5th ed. New York; John Wiley & Sons 1997
  • 46 Liver (including intrahepatic bile ducts) .In: Green F, Page D, Fleming I, et al AJCC Cancer Staging Handbook. 6th ed. New York; Springer 2002: 131-144
  • 47 Izumi R, Shimizu K, Ii T et al.. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.  Gastroenterology. 1994;  106 720-727
  • 48a Llovet J M, Bruix J, Fuster J et al.. Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power.  Hepatology. 1998;  27 1572-1577
  • 48b Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma.  Semin Liver Dis. 2005;  25 171-180
  • 49 Llovet J M, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification.  Semin Liver Dis. 1999;  19 329-338
  • 50 Befeler A S, Di Bisceglie A M. Hepatocellular carcinoma: diagnosis and treatment.  Gastroenterology. 2002;  122 1609-1619
  • 51 Marrero J, Fontana R, Barrat A et al.. Prognosis of hepatocellular carcinoma: comparison of seven staging systems in an American cohort.  Hepatology. 2005;  , In press
  • 52 Vauthey J, Lauwers G, Esnaola N et al.. Simplified staging for hepatocellular carcinoma.  J Clin Oncol. 2002;  20 1527-1536
  • 53 Poon R, Fan S. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients.  Surg Oncol Clin N Am. 2003;  12 35-50
  • 54 Makuuchi M, Hasegawa H, Yamazaki S. Indication of hepatectomy in patients with hepatocellular carcinoma and cirrhosis.  Shindan to Chiryo (in Japanese). 1986;  74 1225-1230
  • 55 Miyagawa S, Mackuuchi M, Kawasaki S et al.. Criteria for safe hepatic resection.  Am J Surg. 1995;  169 589-594
  • 56 Poon R, Fan S T. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome.  Liver Transpl. 2004;  10 S39-S45
  • 57 Bruix J, Castells A, Bosch J et al.. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.  Gastroenterology. 1996;  111 1018-1022
  • 58 Murakami T, Mochizuki K, Nakamura H. Imaging evaluation of the cirrhotic liver.  Semin Liver Dis. 2001;  21 213-224
  • 59 Rizzi P M, Kane P A, Ryder S D et al.. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation.  Gastroenterology. 1994;  107 1425-1429
  • 60 De Carlis L, Giacomoni A, Pirotta V et al.. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation.  J Am Coll Surg. 2003;  196 887-897
  • 61 Burrel M, Llovet J M, Ayuso C et al.. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.  Hepatology. 2003;  38 1034-1042
  • 62 Torzilli G, Olivari N, Moroni E et al.. Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis.  Liver Transpl. 2004;  10 S34-S38
  • 63 Llovet J M, Wurmbach E. Gene expression profile in hepatocellular carcinoma: not yet there.  J Hepatol. 2004;  41 336-339
  • 64 Makuuchi M, Belghiti J B, Belli G et al.. IHPBA concordant classification of primary liver cancer: working group report.  J Hepatobiliary Pancreat Surg. 2003;  10 26-30
  • 65 Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an eastern point of view.  Liver Transpl. 2004;  10 S3-S8
  • 66 Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection.  Jpn J Clin Oncol. 1998;  28 604-608
  • 67 Lee J, Chu I, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.  Hepatology. 2004;  40 667-676
  • 68 Belghiti J, Panis Y, Farges O et al.. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis.  Ann Surg. 1991;  214 114-117
  • 69 Okada S, Shimada K, Yamamoto J et al.. Predictive factors for postoperative recurrence of hepatocellular carcinoma.  Gastroenterology. 1994;  106 1618-1624
  • 70 Adachi E, Maeda T, Matsumata T et al.. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma.  Gastroenterology. 1995;  108 768-775
  • 71 Kumada T, Nakano S, Takeda I et al.. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.  Hepatology. 1997;  25 87-92
  • 72 Imamura H, Matsuyama Y, Tanaka E et al.. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.  J Hepatol. 2003;  38 200-207
  • 73 Iizuka N, Oka M, Yamada-Okabe H et al.. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.  Lancet. 2003;  361 923-929
  • 74 Chen Y, Yeh S H, Chen J T et al.. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma.  Gastroenterology. 2000;  119 431-440
  • 75 Finkelstein S D, Marsh W, Demetris A J et al.. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma.  Hepatology. 2003;  37 871-879
  • 76 Ng I, Guan X, Poon R et al.. Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis.  J Pathol. 2003;  199 345-353
  • 77 Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki K T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.  N Engl J Med. 1996;  334 1561-1567
  • 78 Schwartz J D, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.  Lancet Oncol. 2002;  3 593-603
  • 79 Wu C C, Oho Y Z, Lin W et al.. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal.  Br J Surg. 1995;  82 122-126
  • 80 Yamasaki S, Hasegawa H, Kinoshita H et al.. A prospective randomized trial of preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma.  Jpn J Cancer Res. 1996;  87 206-211
  • 81 Izumi R, Shimizu S, Iyobe T et al.. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.  Hepatology. 1994;  20 295-301
  • 82 Li J Q, Zhang Y K, Zhang W Z et al.. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy.  J Cancer Res Clin Oncol. 1995;  121 364-366
  • 83 Lai E C, Lo C M, Fan S T et al.. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma.  Arch Surg. 1998;  133 183-188
  • 84 Ueno S, Tanabe G, Yoshida K et al.. Postoperative prediction and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis.  Cancer. 1999;  86 248-254
  • 85 Khono H, Nagasue H, Hayashi H et al.. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC).  Hepatogastroenterology. 1996;  43 1405-1409
  • 86 Lau W Y, Leung T W, Ho S K et al.. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.  Lancet. 1999;  353 797-801
  • 87 Yamamoto M, Arii S, Sughara K et al.. Adjuvant oral chemotherapy after curative resection of hepatocellular carcinoma.  Br J Surg. 1996;  83 336-340
  • 88 Ono T, Nagasue N, Kohno H et al.. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.  Semin Oncol. 1997;  24(suppl 6) S6-18
  • 89 Takayama T, Sekine T, Makuuchi M et al.. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
  • 90 Ikeda K, Arase Y, Saitoh S et al.. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer.  Hepatology. 2000;  32 228-232
  • 91 Kubo S, Nishiguchi S, Hirohashi K et al.. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.  Ann Intern Med. 2001;  134 963-967
  • 92 Shiratobi Y, Shiina S, Teratani T et al.. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.  Ann Intern Med. 2003;  138 299-306
  • 93 Lin S M, Lin C J, Hsu C W et al.. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.  Cancer. 2004;  100 376-382
  • 94 Boucher E, Corbinais S, Rolland Y. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.  Hepatology. 2003;  38 1237-1241
  • 95 Majno P E, Sarasin F P, Mentha G. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis.  Hepatology. 2000;  31 899-906
  • 96 Llovet J M, Bruix J, Gores G. Surgical resection vs transplantation for early hepatocellular carcinoma: clues for the best strategy.  Hepatology. 2000;  31 1019-1021
  • 97 Belghiti J, Cortes A, Abdalla E et al.. Resection prior to liver transplantation for hepatocellular carcinoma.  Ann Surg. 2003;  238 885-893
  • 98 Sala M, Fuster J, Llovet J M et al.. High pathological risk of recurrence after surgical resection for HCC. An indication for liver transplantation.  Liver Transpl. 2004;  10 1294-1300
  • 99 Esquivel C O, Iwatsuki S, Gordon R D, Starzl T E. Transplantation for primary liver cancer. In: Wanebo HJ Hepatic and Biliary Cancer. New York; Marcel Dekker 1987: 484
  • 100 Lotze M T, Wanebo H J. Current and future research directions in management of hepatic cancer. In: Wanebo HJ Hepatic and Biliary Cancer. New York; Marcel Dekker 1987: 512
  • 101 Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.  World J Surg. 1991;  15 270-285
  • 102 Iwatsuki S, Starzl T E, Sheahan D G et al.. Hepatic resection versus transplantation for hepatocellular carcinoma.  Ann Surg. 1991;  214 221-228
  • 103 Iwatsuki S, Gordon R D, Shaw Jr B W et al.. Role of liver transplantation in cancer therapy.  Ann Surg. 1985;  202 401-407
  • 104 Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis.  Ann Surg. 1993;  218 145-151
  • 105 Bruix J, Llovet J M. Prognostic prediction and treatment strategy in hepatocellular carcinoma.  Hepatology. 2002;  35 519-524
  • 106 Roayaie S, Ben-Haim M, Fishbein T M et al.. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a Western experience.  Ann Surg Oncol. 2000;  7 764-770
  • 107 Llovet J M, Sala M, Fuster J et al.. Predictors of drop-out and survival of patients with hepatocellular carcinoma candidates for liver transplantation.  Hepatology. 2003;  38 763A
  • 108 Yao F, Bass N, Nikolai B et al.. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.  Liver Transpl. 2003;  9 684-692
  • 109 Maddala Y K, Stadheim L, Andrews J C et al.. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.  Liver Transpl. 2004;  10 449-455
  • 110 Bruix J, Fuster J, Llovet J M. Liver transplantation for hepatocellular carcinoma: Foucault pendulum vs evidence-based decision.  Liver Transpl. 2003;  9 700-702
  • 111 Marsh J W, Geller D, Finkelstein S et al.. Role of liver transplantation for hepatobiliary malignant disorders.  Lancet Oncol. 2004;  5 480-488
  • 112 Schwartz M. Liver transplantation for hepatocellular carcinoma.  Gastroenterology. 2004;  127 S268-S276
  • 113 Stone M J, Klintmalm G B, Polter D et al.. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients.  Gastroenterology. 1993;  104 196-202
  • 114 Olthoff K M, Rosove M H, Shackleton C R et al.. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.  Ann Surg. 1995;  221 734-741
  • 115 Majno P E, Adam R, Bismuth H et al.. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.  Ann Surg. 1997;  226 688-701
  • 116 Oldhafer K J, Chavan A, Fruhauf N R et al.. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?.  J Hepatol. 1998;  29 953-959
  • 117 Graziadei I W, Sandmueller H, Waldenberger P et al.. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.  Liver Transpl. 2003;  9 557-563
  • 118 Mazzaferro V, Battiston C, Perrone S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.  Ann Surg. 2004;  240 900-909
  • 119 Lu D S, Yu N C, Raman S S et al.. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.  Radiology. 2005;  234 954-960
  • 120 Llovet J M, Mas X, Aponte J et al.. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation.  Gut. 2002;  50 123-128
  • 121 Roayaie S, Llovet J M. Extended indications for liver transplantation in hepatocellular carcinoma.  Clin Liver Dis. 2005;  9 315-328
  • 122 Miller C M, Gondolesi G E, Florman S et al.. One hundred nine living donor liver transplants in adults and children: a single-center experience.  Ann Surg. 2001;  234 301-312
  • 123 Marcos A. Right lobe living donor liver transplantation: a review.  Liver Transpl. 2000;  6 3-20
  • 124 Trotter J, Wachs M, Everson G, Kam I. Adult-to-adult transplantation of the right hepatic lobe from living donor.  N Engl J Med. 2002;  346 1074-1082
  • 125 Sugawara Y, Makuuchi M, Takayama T. Safe donor hepatectomy for living related liver transplantation.  Liver Transpl. 2002;  8 58-62
  • 126 Ben-Haim M, Emre S, Fishbein T M et al.. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease.  Liver Transpl. 2001;  7 948-953
  • 127 Sarasin F, Majno P, Llovet J M, Mentha J, Bruix J, Hadengue A. Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness perspective.  Hepatology. 2001;  33 1073-1079
  • 128 Garcia-Retortillo M, Forns X, Llovet J M et al.. Hepatitis C recurrence is more severe after living donor transplantation compared to cadaveric liver transplantation.  Hepatology. 2004;  40 699-707
  • 129 Bozorgzadeh A, Jain A, Ryan C et al.. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus.  Transplantation. 2004;  77 1066-1107
  • 130 Gaglio  P J, Malireddy S, Levitt B S. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors.  Liver Transpl. 2003;  9 1028-1035
  • 131 Forns Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation.  J Hepatol. 2004;  41 2-10
  • 132 Starzl T E, Marchioro T L, Faris T D. Liver transplantation.  Ann Intern Med. 1966;  64 473-477

Josep M LlovetM.D. 

Division of Liver Diseases, RM Transplantation Institute, Mount Sinai School of Medicine

1425 Madison Ave, 11F-70, Box:1104

New York, NY10029

Email: Josep.Llovet@mssm.edu

    >